The evidence provides rare official confirmation that Alibaba functions as part of the CCP’s broader apparatus of social control, blurring the line between commercial cybersecurity and the Party-state’s political-legal enforcement system.
Breaking!!! Alibaba’s Security Arm Self Reveals Deep Integration with CCP’s Political-Legal System by CPA Jim
Read on Substack
Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. is a Shanxi-based biotechnology company focused on functional protein materials, including recombinant humanized type III collagen and anti-HPV protein applications. The company maintains joint research platforms with major Chinese universities and has expanded into AI-enabled biomedical and medical aesthetics applications.
Zhang Xingdong serves as Chief Scientific Advisor on biomaterials for Jinbo. He is a prominent biomaterials expert associated with national-level biomedical engineering platforms and has participated in industry forums alongside PLA medical representatives and Jinbo leadership.
The People's Liberation Army Joint Logistic Support Force (JLSF) was established in 2016 under reforms directed by Xi Jinping as Chairman of the Central Military Commission. It oversees unified logistics support across the PLA, including transportation, supply, and medical systems. Military medical institutions, including major PLA hospital centers, operate within this integrated support structure.
Jiang Shibo, Director of the Institute of Medical Microbiology at Fudan University, serves as Chief Scientist for Jinbo. Public records show that he has co-applied for patents and co-authored research with institutes under the Academy of Military Medical Sciences and with the PLA Center for Disease Control and Prevention.
The Academy of Military Medical Sciences (AMMS) is a PLA-affiliated biomedical research body historically responsible for military medical research, including microbiology, epidemiology, and bioengineering. Institutes under AMMS have appeared in joint patent filings and academic publications involving Jiang Shibo and associated research entities.
For a detailed analysis of how these institutional links intersect across corporate, academic, and PLA structures, please read the full article here:#Democracy #Christ #Peace #Freedom #Liberty #Humanrights #人权 #法治 #宪政 #独立审计 #司法独立 #联邦制 #独立自治
In retrospect, the September 2019 symposium was not merely an academic gathering.
The conference included not only university scientists and civilian research institutes, but also researchers affiliated with China’s military research system, including senior personnel from the People’s Liberation Army’s Academy of Military Medical Sciences.
The presence of high-level virologists working on emerging pathogens, viral mutation mechanisms, cross-species transmission, and translational applications — combined with participation from military-linked research institutions — adds an additional layer of geopolitical and biosecurity relevance.
While the event was publicly framed as an international scientific exchange, the institutional composition of its speakers reflects the intersection of civilian, state, and military research structures within China’s virology ecosystem.
Given the timing — only weeks before the first known COVID-19 cases — the symposium represents a significant data point in understanding the broader research landscape in Wuhan immediately prior to the pandemic.
中共党员陈薇是中国人民解放军少将，军事医学科学院生物工程研究所所长、研究员，2001年“9·11事件”后不久作为中国人民解放军重大专项的首席科学家，获得500多万元的资助，2006年凭借一项所谓反恐生化研究以第一完成人身份获得中国人民解放军军队科学技术进步奖一等奖。
Feng Jianwei, Permanent Honorary President of the Shandong Fellowship Association of Southern U.S.A., has played a role in organizing transnational medical initiatives linking U.S.-based physicians with institutions in the People’s Republic of China.
In 2005, he participated in founding the American Houpu Biomedical Education and Development System, which reportedly facilitated recruitment into state-sponsored talent initiatives, including the “Thousand Talents Plan” and “Changjiang Scholars Program.”
In 2015, Feng and other U.S.-based Chinese medical professionals launched the American Chinese Physicians Network Hospital.
That same year and following years, Feng received high-level political visibility within the CCP system, including meetings with senior national leadership and participation in the Chinese People’s Political Consultative Conference (CPPCC). Such recognition reflects incorporation into formal united front and overseas professional engagement channels.
On December 26, 2015, Zhejiang University School of Medicine’s Second Affiliated Hospital (ZJU-2 Hospital) and the American Chinese Physicians Network Hospital jointly established the “China Southern Center.”
On May 20, 2021, Zhejiang University School of Medicine issued a public announcement regarding its joint doctoral training program with the Academy of Military Sciences (AMS).
The notice confirms:
Formal joint recruitment procedures
Shared evaluation by ZJU and AMS faculty teams
In-person written exams and interviews at ZJU’s Hangzhou campus
Alignment with ZJU’s official doctoral admissions framework
Two AMS-affiliated “innovation teams” were explicitly named:
Zhang Xue-Min Innovation Team
Chen Wei Innovation Team
In Shanghai, April 14–17, 2019, the 2019 Workshop on Cosmetic Risk Assessment and Regulatory Application of Non-Animal Testing Technology brought together Chinese and international toxicology experts, corporate R&D representatives, and animal welfare organizations. The event was hosted by the Society of Toxicological Alternatives & Translational Toxicology (CSOT) and the Society of Toxicity Testing and Alternative Methods (CEMS), with sponsorship from Humane Society International, L’Oréal R&I China, Mary Kay (China) Co., Ltd., and Shanghai Medicilon Inc..
The organizing committee included: Conference Chair Peng Shuangqing, Secretaries Xiaoting Qu and Yi Shuai, and members such as Jiabin Guo (co-author on PLA-affiliated research), Kate Willett, and multiple other academics and industry representatives. The workshop program featured plenary lectures and focused sessions led by international and Chinese experts:
Gerald Renner (Cosmetic Europe) on EU regulatory implementation;
Kate Willett (Humane Society International) on non-animal safety assessment and OECD Adverse Outcome Pathway programs;
Vera Rogiers (Vrije Universiteit Brussel / EU SCCS) on in vitro toxicology and cosmetic risk assessment;
James Wakefield (Delphic HSE) on regional toxicological safety and compliance in APAC;
Lit-Hsin Loo (A*STAR, Singapore) on toxicity mode-of-action profiling;
Yuan Gao (P&G) and Jin Li (Unilever, UK) on non-animal testing integration and pathway-based risk assessment;
Taoran Xing (L’Oréal APAC) and Liping Hu (Johnson & Johnson, China) on regulatory product safety evaluation in the Asia-Pacific region.
Other key speakers at the 2019 Workshop on Cosmetic Risk Assessment and Regulatory Application of Non-Animal Testing Technology included internationally recognized experts in alternative testing and toxicology. Donna Macmillan, Principal Scientist at Lhasa Limited, leads the skin sensitization research team and promotes collaborative data-sharing to improve predictive toxicity models. Hajime Kojima, Secretary General of the Japanese Center for the Validation of Alternative Methods (JaCVAM) and Section Chief of the Division of Risk Assessment at Japan’s Biological Safety Research Center, also serves as a councilor for multiple Japanese toxicology and alternative methods societies and is an OECD expert on skin and eye irritation, sensitization, and endocrine disruptor testing. Carl Westmoreland, Director of Science & Technology at Unilever’s Safety and Environmental Assurance Centre (SEAC), focuses on delivering consumer safety without animal testing and is a member of the European Scientific Advisory Committee for ECVAM. Nathalie Alépée of L’Oréal R&I France has over twenty years of leadership in investigative toxicology, contributing to EU alternative testing projects, ESAC, and OECD regulatory guidance.
